218 related articles for article (PubMed ID: 9129932)
1. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.
Imada S; Akaza H; Ami Y; Koiso K; Ideyama Y; Takenaka T
Eur Urol; 1997; 31(3):360-4. PubMed ID: 9129932
[TBL] [Abstract][Full Text] [Related]
2. [Effects of androgen regulation system on bladder carcinogenesis in male mice].
Imada S; Akaza H; Otani M; Koiso K
Nihon Hinyokika Gakkai Zasshi; 1995 Nov; 86(11):1666-72. PubMed ID: 8551710
[TBL] [Abstract][Full Text] [Related]
3. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
Zaccheo T; Giudici D; di Salle E
Prostate; 1997 Feb; 30(2):85-91. PubMed ID: 9051146
[TBL] [Abstract][Full Text] [Related]
4. [Effects of luteinizing hormone-releasing hormone agonist on bladder carcinogenesis in male rats].
Matsuki K; Akaza H; Aso Y
Nihon Hinyokika Gakkai Zasshi; 1992 Sep; 83(9):1452-8. PubMed ID: 1434288
[TBL] [Abstract][Full Text] [Related]
5. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.
Kirby R; Robertson C; Turkes A; Griffiths K; Denis LJ; Boyle P; Altwein J; Schröder F
Prostate; 1999 Jul; 40(2):105-14. PubMed ID: 10386471
[TBL] [Abstract][Full Text] [Related]
6. [Effects of LH-RH analogue on pituitary-testicular axis and bladder carcinogenesis of BBN administered male rats].
Matsuki K; Akaza H; Munakata A; Kameyama S; Aso Y
Nihon Hinyokika Gakkai Zasshi; 1989 Jul; 80(7):1051-8. PubMed ID: 2514311
[TBL] [Abstract][Full Text] [Related]
7. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
[TBL] [Abstract][Full Text] [Related]
8. Effect of the 5 alpha-reductase inhibitor PNU 156765, alone or in combination with flutamide, in the Dunning R3327 prostatic carcinoma model in rats.
Zaccheo T; Giudici D; Panzeri A; di Salle E
Chemotherapy; 1998; 44(4):284-92. PubMed ID: 9681205
[TBL] [Abstract][Full Text] [Related]
9. Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer.
Akaza H; Isaka S; Usami M; Kanetake H; Kotake T; Koiso K; Aso Y
Int J Urol; 1996 Nov; 3(6):468-71. PubMed ID: 9170575
[TBL] [Abstract][Full Text] [Related]
10. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Leibowitz RL; Tucker SJ
Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
Cho YM; Takahashi S; Asamoto M; Suzuki S; Tang M; Shirai T
Prostate Cancer Prostatic Dis; 2007; 10(4):378-83. PubMed ID: 17457304
[TBL] [Abstract][Full Text] [Related]
13. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
[TBL] [Abstract][Full Text] [Related]
14. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
[TBL] [Abstract][Full Text] [Related]
15. Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate.
Shibata Y; Ono Y; Kashiwagi B; Suzuki K; Fukabori Y; Honma S; Yamanaka H
Urology; 2003 Nov; 62(5):942-6. PubMed ID: 14624931
[TBL] [Abstract][Full Text] [Related]
16. Replacement of surgical castration by GnRH-inhibition or Leydig cell ablation in the male rat Hershberger antiandrogen assay.
Ashby J; Lefevre PA; Deghenghi R; Wallis N
Regul Toxicol Pharmacol; 2001 Oct; 34(2):188-203. PubMed ID: 11603962
[TBL] [Abstract][Full Text] [Related]
17. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
Tomura A; Kuroiwa S; Okada M; Abe F
Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
[TBL] [Abstract][Full Text] [Related]
18. [Effect of liarozole on the cell proliferation activity in the rat urinary bladder epithelium induced by N-butyl-N-(4-hydroxybutyl) nitrosamine].
Nagae H; Otawara Y; Suzuki K; Fujita K
Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):838-42. PubMed ID: 10565163
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
Zaccheo T; Giudici D; di Salle E
Endocr Relat Cancer; 1999 Sep; 6(3):429-35. PubMed ID: 10516856
[TBL] [Abstract][Full Text] [Related]
20. Finasteride inhibits 5 alpha-reductase activity in human dermal fibroblasts: prediction of its therapeutic application in androgen-related skin diseases.
Nguyen QH; Chen T; Wang X; Chen Y; Chien P
Int J Dermatol; 1995 Oct; 34(10):720-5. PubMed ID: 8537164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
